Top-Rated StocksTop-RatedNASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $15.18 +0.37 (+2.50%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$15.16 -0.03 (-0.16%) As of 08/27/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Oruka Therapeutics Stock (NASDAQ:ORKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$14.63▼$15.6350-Day Range$10.90▼$15.5052-Week Range$5.49▼$46.20Volume177,627 shsAverage Volume145,840 shsMarket Capitalization$568.49 millionP/E RatioN/ADividend YieldN/APrice Target$40.38Consensus RatingBuy Company Overview Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 570th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOruka Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Oruka Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ORKA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ORKA. News and Social Media1.8 / 5News Sentiment0.23 News SentimentOruka Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.69% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORKA Stock News HeadlinesHC Wainwright Issues Negative Estimate for ORKA EarningsAugust 22, 2025 | americanbankingnews.comOruka Therapeutics initiated with a Buy at Clear StreetAugust 21, 2025 | msn.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. | Banyan Hill Publishing (Ad)HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)August 20, 2025 | americanbankingnews.comOruka Therapeutics (ORKA) Receives a Buy from H.C. WainwrightAugust 19, 2025 | theglobeandmail.comOruka Therapeutics (NASDAQ:ORKA) Rating Lowered to "Sell" at Wall Street ZenAugust 18, 2025 | americanbankingnews.comQ3 EPS Estimate for Oruka Therapeutics Lowered by AnalystAugust 17, 2025 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth PlansAugust 15, 2025 | finance.yahoo.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $19.39 on January 1st, 2025. Since then, ORKA shares have decreased by 21.7% and is now trading at $15.18. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. Who are Oruka Therapeutics' major shareholders? Top institutional shareholders of Oruka Therapeutics include Braidwell LP (4.07%), Franklin Resources Inc. (2.71%), Geode Capital Management LLC (1.89%) and Affinity Asset Advisors LLC (1.61%). View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings8/11/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$40.38 High Price Target$49.00 Low Price Target$20.00 Potential Upside/Downside+166.0%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.26% Return on Assets-24.16% Debt Debt-to-Equity RatioN/A Current Ratio27.42 Quick Ratio27.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.10 per share Price / Book1.67Miscellaneous Outstanding Shares37,450,000Free Float28,204,000Market Cap$568.49 million OptionableN/A Beta-0.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ORKA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.